Dosing & Administration

Recommended approach to dosing:
Start with it. Stay with it.™

At early signs of degenerative joint disease, veterinarians can administer Adequan® I.M. at the approved dose (500 mg) to help achieve improvement shown in studies.1,2 After the initial series, veterinarians and owners alike should keep monitoring the horse’s joint health and mobility. Veterinarians may repeat the approved dosing series as needed upon recurrence of the clinical signs of DJD.

Adequan Equine veterinarian giving horse injection

Quickly reaches your horse’s joints to deliver relief.

After intramuscular administration, Adequan® I.M. is well absorbed, goes to work fast and keeps working for up to 96 hours.2

Adequan Equine horse healthy joint graphic

Hyaluronic Acid (HA) levels nearly doubled at 48 hours with significant increases noted from 24 up to 96 hours.2
Clinical significance of the above results is unknown.

Reduced lameness. Improved carpal flexion.1

In a Dose Titration Study, the benefits of adhering to the dosing regimen delivered over 50% improvement in maximum carpal flexion.1

Adequan Equine carpal flexion improvement graph

A placebo-controlled, blinded dose titration study was conducted in a total of 36 healthy, mature horses that were either Quarter horses or Thoroughbreds. An induced adjuvant carpitis in the horse was used to assess the dose and efficacy of the intramuscular administration of Adequan® I.M. The adjuvant induced arthritis was produced with a single intraarticular injection of 0.5 mL of Freunds adjuvant. The various treatments comprised sterile saline solution as a placebo control and 50 mg, 125 mg, 250 mg, 500 mg and 1,000 mg of the active drug substance Adequan® I.M. dissolved in sterile water. Injections were given every 4 days for a total of 7 injections. Treatment followed a 10 day acclimation period and a five day model induction period. This study data is provided from the U.S. NADA FOI summary.1

Adequan® I.M. brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS
Adequan® I.M. is recommended for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses.
IMPORTANT SAFETY INFORMATION
Adequan® I.M. is for veterinary use only. The prescribing information contains complete use information which includes dosing, contraindications, warnings and cautions. Always read, understand and follow label and use directions. PLEASE CONSULT the Full Prescribing Information.
1. Freedom of Information Summary, Adequan® I.M. NADA 140-901, https://animaldrugsatfda.fda.gov/adafda/app/search /public/document/downloadFoi/2489
2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
3. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
Animal Health Logo